> Visualmix

Vaccine against IBR and Infectious Keratoconjunctivitis.

Optimal immune response against eye diseases. The MBS molecular verification of the genes of interest (gB gene) applied in Visualmix is ​​key to producing the main immunogenic glycoproteins in IBR, responsible for the generation of neutralizing antibodies.

3 ml.
Subcutaneous route

Primary vaccinations: from 3 months of age, 2 doses 21 days apart. Primarily vaccinated pregnant females: 2 doses 21 days apart. Revaccinate semi-annually.


Bottle containing 240 ml / 80 doses or 90 ml / 30 doses


Inactivated cultures of HVB type I and Moraxella bovis. Adjuvant: aluminum gel.